Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.80 |
| ▸ | MEN1 | O00255 | 6/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.80 |
| ▸ | HPGD | P15428 | 3/20 | 0.80 |
| ▸ | THRB | P10828 | 2/20 | 0.80 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.68 |
| ▸ | RAB9A | P51151 | 4/20 | 0.68 |
| ▸ | NPC1 | O15118 | 3/20 | 0.68 |
| ▸ | GAA | P10253 | 2/20 | 0.68 |
| ▸ | CRHBP | P24387 | 1/20 | 0.61 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.61 |
| ▸ | NAMPT | P43490 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | CA12 | O43570 | 1/20 | 0.57 |
| ▸ | CA9 | Q16790 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | GFER | P55789 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2814707 | 0.87 | MAPT (0.62) | MAPTALDH1A1MEN1KMT2AHPGD | |
| SCHEMBL4911144 | 0.87 | MAPT (0.66) | MAPTALDH1A1MEN1KMT2AHPGD | |
| SCHEMBL12964144 | 0.87 | MAPT (0.66) | MAPTALDH1A1MEN1KMT2AHPGD | |
| SCHEMBL2197321 | 0.85 | ALDH1A1 (0.70) | MAPTALDH1A1MEN1KMT2AHPGD | |
| SCHEMBL7748617 | 0.85 | CYP1A2 (0.71) | MAPTALDH1A1MEN1KMT2AHPGD | |
| SCHEMBL5793276 | 0.83 | MAPT (0.62) | MAPTALDH1A1MEN1KMT2AHPGD | |
| SCHEMBL10941324 | 0.83 | NAMPT (0.69) | MAPTALDH1A1MEN1KMT2AHPGD | |
| SCHEMBL12549885 | 0.82 | RAB9A (0.88) | MAPTALDH1A1MEN1KMT2AHPGD | |
| SCHEMBL1019967 | 0.82 | SMN1; SMN2 (0.78) | MAPTALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL20389370 | 0.82 | NAMPT (0.76) | MAPTALDH1A1MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3568390-B1 | SMALL MOLECULE ACTIVATORS OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) AND USES THEREOF | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INST (US) | 2024-03-06 | — | — | EP | disclosed |
| US-11806337-B2 | Small molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and uses thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2023-11-07 | — | — | US | disclosed |
| US-11806337-B2 | Small molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and uses thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2023-11-07 | — | — | US | disclosed |
| US-11806337-B2 | Small molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and uses thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2023-11-07 | — | — | US | disclosed |
| US-20230116770-A1 | SMALL MOLECULE ACTIVATORS OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2023-04-13 | — | — | US | disclosed |
| US-11452717-B2 | Small molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and uses thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2022-09-27 | — | — | US | disclosed |
| US-20210161873-A1 | SMALL MOLECULE ACTIVATORS OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2021-06-03 | — | — | US | disclosed |
| US-20210161873-A1 | SMALL MOLECULE ACTIVATORS OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2021-06-03 | — | — | US | disclosed |
| EP-3568390-A1 | SMALL MOLECULE ACTIVATORS OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2019-11-20 | — | — | EP | disclosed |
| WO-2018132372-A1 | SMALL MOLECULE ACTIVATORS OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2018-07-19 | — | — | WO | disclosed |
| WO-2018132372-A1 | SMALL MOLECULE ACTIVATORS OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2018-07-19 | — | — | WO | disclosed |
| US-9018393-B2 | Method for preparing 2-(N-substituted)-amino-benzimidazole derivatives | ABA CHEMICALS CORPORATION (CN) | 2015-04-28 | — | — | US | disclosed |
| EP-0622361-B1 | Heterocyclic compounds as bradykinin antagonists | FUJISAWA PHARMACEUTICAL CO (JP) | 2001-10-04 | — | — | EP | disclosed |
| US-6169095-B1 | FOR PREVENTION AND/OR TREATMENT OF BRADYKININ OR ITS ANALOGUES MEDIATED DISEASES IN THE EYE, SUCH AS ALLERGY, INFLAMMATION AND PAIN OF THE EYE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-01-02 | — | — | US | disclosed |
| US-5922711-A | ANTIALLERGENS, ANTIINFLAMMATORY AGENTS, AUTOIMMUNE DISEASES, SHOCK OR ANALGESICS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-07-13 | — | — | US | disclosed |
| US-5708173-A | PREPARATION OF SUBSTITUTED QUINOLINE COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-01-13 | — | — | US | disclosed |
| US-5563162-A | CAN BE ADMINISTERD FOR THE TREATMENT OF ALLERGY, INFLAMMATION, AUTOIMMUNE DISEASES, SHOCK OR PAIN IN ANIMALS AND HUMANS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-10-08 | — | — | US | disclosed |
| EP-0622361-A1 | Heterocyclic compounds as bradykinin antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11452717-B2 | Small molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and uses thereof | NAMPT, NAPRT, NNT | MAPT 369/4885ALDH1A1 1943/4885MEN1 2154/4885 |
| US-20210161873-A1 | SMALL MOLECULE ACTIVATORS OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) AND USES THEREOF | NAMPT, NAPRT, NNT | MAPT 369/4885ALDH1A1 1943/4885MEN1 2154/4885 |
| US-11806337-B2 | Small molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and uses thereof | NAMPT, NAPRT, NNT | MAPT 369/4885ALDH1A1 1943/4885MEN1 2154/4885 |
| US-20230116770-A1 | SMALL MOLECULE ACTIVATORS OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) AND USES THEREOF | NAMPT, NAPRT, NNT | MAPT 369/4885ALDH1A1 1943/4885MEN1 2154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.